Advisory Services Network’s Heron Therapeutics HRTX Stock Holding History

Advisory Services Network’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.36K	Buy	19,580 +17,662	+921%	+$14.2K	﹤0.01%	2138
2026 Q1	$1.53K	Sell	1,918 -16,956	-90%	-$19.6K	﹤0.01%	4204
2025 Q4	$24.5K	Buy	18,874 +18,114	+2,383%	+$22.4K	﹤0.01%	1789
2025 Q3	$958	Buy	+760	New	+$1.21K	﹤0.01%	3939
2024 Q1	–	Sell	-1,479	Closed	-$2.51K	–	2431
2023 Q4	$2.51K	Buy	+1,479	New	+$1.63K	﹤0.01%	3336
2023 Q2	–	Sell	-760	Closed	-$1.15K	–	2418
2023 Q1	$1.15K	Sell	760 -200	-21%	-$501	﹤0.01%	3588
2022 Q4	$2.4K	Buy	+960	New	+$3.09K	﹤0.01%	3379

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Advisory Services Network's HRTX Position: Q2 2026 in Review

Advisory Services Network increased its Heron Therapeutics (HRTX) stake by 921% in Q2 2026, buying an estimated $14.2K and bringing the position to 19,580 shares worth $8.36K. The position accounts for ﹤0.01% of the portfolio, ranked #2138.

Advisory Services Network first reported a position in HRTX in Q4 2022 and has held it in 7 quarters since. The position peaked at $24.5K in Q4 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

Advisory Services Network held 19,580 shares of Heron Therapeutics worth $8.36K as of Q2 2026.
Advisory Services Network bought 17,662 Heron Therapeutics shares in Q2 2026, an estimated $14.2K.
Heron Therapeutics made up ﹤0.01% of Advisory Services Network's portfolio in Q2 2026, its #2138 holding.
Advisory Services Network first reported a position in Heron Therapeutics in Q4 2022 and has held it in 7 quarters since.
Advisory Services Network's Heron Therapeutics position peaked at $24.5K in Q4 2025.
163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.